Bethesda 4 (Follicular Neoplasm): Molecular Testing and Surgical Decision in Thyroid Nodule

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was developed at the 2007 NCI workshop, updated 2017. Standardised reporting system for thyroid FNA cytology. Global gold standard.

Categories and malignancy risk (2017): I — non-diagnostic (5-10%), II — benign (0-3%), III — AUS/FLUS (10-30%), IV — follicular neoplasm or suspicious for follicular neoplasm (25-40%), V — suspicious for malignancy (50-75%), VI — malignant (97-99%).

Bethesda IV — Follicular Neoplasm (FN) or Suspicious for Follicular Neoplasm (SFN): follicular pattern (microfollicles, small follicles, cell clusters) + cellular crowding + scant colloid on cytology. No abnormal nuclear features (otherwise Bethesda V or VI). Follicular adenoma and follicular carcinoma cannot be distinguished on cytology — histology required (capsular penetration + vascular invasion).

Hürthle cell neoplasm (Bethesda IVH — oncocytic neoplasm): large polygonal cells, abundant granular eosinophilic cytoplasm (mitochondria-rich), large nucleoli. Hürthle adenoma vs carcinoma — again only histology. Separate category from FN.

Clinical and ultrasound correlation: Bethesda IV usually "cold" nodule (low activity on radionuclide scan); "hot" nodule resembles toxic nodular goitre, lower malignancy risk. Ultrasound features: ATA (American Thyroid Association) 2015 classification — solid hypoechoic, microcalcifications, taller-than-wide, irregular margin, extrathyroidal extension are high-risk features.

FNA technique: ultrasound-guided, 22-25 gauge fine needle, 2-4 samples. Cytologist must be expert (TBSRTC standard). Non-diagnostic (category I) rate depends on operator + cytologist experience (5-15%).

Follicular carcinoma characteristics: encapsulated (vs papillary — unencapsulated, infiltrative), haematogenous spread (vs papillary — lymphatic), mean age 50-55 (older than papillary), female >> male, higher incidence in iodine-deficient areas (Turkey was previously iodine-deficient — salt iodination has reduced it). Prognosis: minimally invasive (only capsular penetration, no vascular invasion) excellent, 10-year survival >95%; widely invasive (vascular invasion) moderate-high risk, 10-year survival 50-70%. We expand on the clinical framework in our thyroid surgery programme.

60-75% of Bethesda IV nodules are pathologically benign (follicular adenoma); but since this cannot be told preoperatively, traditionally all undergo surgery. Molecular tests were developed to address this "over-surgery" problem.

Afirma Gene Sequencing Classifier (GSC) — 2018 version: RNA expression of 10,000+ genes. Binary result: benign or suspicious. Benign negative predictive value (NPV) 94% — meaning malignancy chance 6% if benign result (significantly below population risk, surveillance appropriate). Suspicious result implies 50% malignancy — surgery planned. Available in some Turkish private labs.

ThyroSeq v3 — 2018 version: 112-gene panel — mutations (BRAF, RAS — H/K/N, TERT, TP53, PIK3CA, PTEN, AKT1, EIF1AX, DICER1), gene fusions (RET/PTC, PAX8/PPARγ, NTRK, ALK), expression, copy number. Result: negative or positive (alteration specified). Negative NPV 97% — benign management. Positive predicts cancer subtype (e.g. RAS — follicular; BRAF V600E — papillary).

ThyGenX (mutation panel) + ThyraMIR (miRNA expression) combined: ThyGenX 8-gene mutation + fusion panel; ThyraMIR 10 miRNA expressions. Combined accuracy high. More common in USA.

RosettaGX Reveal — miRNA-based: 24 miRNA expression. Benign NPV 91%.

Comparison — performance: Afirma GSC + ThyroSeq v3 — most benign results are truly benign (high postoperative histology concordance in operated cases). Studies show 40-60% of Bethesda IV nodules give benign molecular result → surgery avoided. Economic impact: surgery + hospitalisation + workforce loss + complications (RLN palsy, hypoparathyroidism) — far exceed molecular test cost.

Molecular test limitations: cost (1,500-5,000 USD US, 8,000-15,000 TL in private Turkish labs), turnaround (1-3 weeks), sample inadequacy (RNA quality), some subsets (Hürthle cell neoplasm) lower performance (especially older Afirma; better with GSC), false-negative possibility (3-6% missed cancer).

Usage algorithm: Bethesda IV FNA result → if high-risk ultrasound features then direct surgery (no molecular test); moderate-low risk + patient preference → molecular test → benign surveillance, suspicious surgery. Patient and physician share risk-benefit (surgery vs observation) decision.

Clinical decision factors — beyond molecular tests: nodule size (>4 cm higher malignancy risk, direct surgery considered), bilateral nodules, family thyroid cancer (especially medullary — RET mutation), radiation history (head-neck, childhood), TSH (high TSH linked to malignancy), thyroglobulin (high value suspicion), growth rate (>50% in 3 months suspicious).

Paediatric Bethesda IV: all paediatric nodules carry higher malignancy risk (papillary more common). Paediatric Bethesda IV 30-50% malignancy — surgery standard (paediatric molecular data limited).

Surgical decision is the integrated assessment of molecular test (if available) + nodule characteristics + patient preference. ATA 2015 + 2025 (recent updates) recommend single-nodule approach — lobectomy is the modern trend.

Lobectomy (hemithyroidectomy + isthmusectomy) indications: (1) Unilateral nodule; (2) <4 cm; (3) No family thyroid cancer; (4) No radiation history; (5) Contralateral lobe normal or with small benign nodule; (6) Patient preference (lower postop hormone need); (7) Molecular test not negative but surgery chosen.

Total thyroidectomy indications: (1) Nodule >4 cm; (2) Bilateral nodules; (3) Family thyroid cancer (especially medullary — RET); (4) Head-neck radiation history (childhood); (5) ATA high-risk ultrasound features; (6) Patient preference (single-stage); (7) Thyroiditis background (Hashimoto + nodule — multifocal cancer risk).

Lobectomy advantages: postop hypothyroidism incidence 15-25% (half thyroid may suffice); halved parathyroid + RLN risk (one-sided dissection); shorter operating time; faster recovery; same scar size (Kocher midline — no size difference).

Total thyroidectomy advantages: full thyroglobulin (Tg) surveillance possible — if cancer, RAI ablation and Tg follow-up; avoid second surgery (completion after lobectomy if pathology shows cancer); single-stage solution for bilateral nodules.

Surgical technique — modern: (1) Kocher incision (cervical line, 4-6 cm); (2) Subplatysmal flap; (3) Midline retraction of strap muscles (not divided); (4) Thyroid lobe mobilisation — ligate upper pole arteries (superior thyroid); (5) Recurrent laryngeal nerve (RLN) identification + protection — modern gold standard (intraoperative neuromonitoring — IONM, 100% nerve visualisation); (6) Parathyroid identification + protection (4 glands; in-situ vascularity preservation or autotransplantation if needed); (7) Berry ligament dissection (RLN near trachea entry); (8) Thyroid lobe freed, removed; (9) Haemostasis, drain as needed, layered closure.

Surgical complications: RLN palsy (transient 5-7%, permanent 1-2% — reduced with modern IONM), hypoparathyroidism (transient post-total 20-30%, permanent 2-3% — autotransplantation reduces), haematoma (urgent intervention — neck swelling + respiratory distress), seroma (drain or aspirate), infection (rare <1%), hypertrophic or keloid scar (depends on skin type).

Postoperative care: overnight stay (single lobectomy sometimes day-case), serum calcium monitoring (post-total — for hypocalcaemia symptoms), oral calcium + vitamin D started (usually 1 month), levothyroxine started (post-total — for normalising TSH and adjuvant suppression). Wound care, gradual physical activity, sutures removed or absorbed 7-10 days.

Pathology result — adjuvant decision: follicular adenoma (benign) → treatment ends, annual contralateral US after lobectomy. Follicular carcinoma minimally invasive (capsule only, <4 foci vascular invasion) → low risk, lobectomy sufficient + surveillance. Widely invasive (>4 foci vascular invasion or extensive capsule invasion) → completion total thyroidectomy (if lobectomy first) + RAI ablation (30-100 mCi) + TSH suppression (TSH <0.1) + Tg + neck US follow-up.

Hürthle cell carcinoma: more aggressive (higher metastasis vs follicular), lower RAI response. Management: total thyroidectomy + neck node screening + selective dissection as indicated + RAI trial (accept reduced response) + TSH suppression.

Turkish endocrine surgery practice: major university + private hospital endocrine surgery centres experienced in Bethesda IV. IONM (intraoperative nerve monitoring) is standard in modern centres. Multidisciplinary decision (endocrinologist + cytologist + surgeon + nuclear medicine + radiology). Patient information + shared decision — central to Bethesda IV management. For the related clinical reference, see thyroid cancer page.

Follow-up planned by pathology. After follicular adenoma (benign) diagnosis: annual contralateral US after lobectomy (new nodule monitoring); after total thyroidectomy annual Tg + Tg antibodies (TgAb) (Tg <0.2 ng/mL target — no residual cancer); levothyroxine to normal-range TSH.

After follicular carcinoma (minimally invasive) — low risk: lobectomy sufficient + 6-12 monthly Tg + neck US (annual 5 years, then 2-yearly 5 years, then 5-yearly). Tg rise or new US lesion → reassessment (RAI scan, further imaging, biopsy).

After follicular carcinoma (widely invasive) or high-risk — high risk: total thyroidectomy + RAI ablation (30-100 mCi 1 month later) + TSH suppression (levothyroxine adjusted — TSH <0.1) + thyroglobulin + Tg antibody + neck US 6-monthly (first 2 years), then annual. Suspicious findings → diagnostic RAI scan, imaging (CT, MR, FDG-PET).

Levothyroxine (LT4) — postoperative: lifelong after total thyroidectomy (1.6 μg/kg/day start, titrate by TSH). After lobectomy 20-30% develop hypothyroidism (annual TSH); supplement when needed. In cancer, TSH suppression (high risk — TSH <0.1; low risk — TSH 0.1-0.5; benign — TSH normal range).

Life expectancy: follicular adenoma — lifelong no problem (after lobectomy). Follicular carcinoma minimally invasive — 10-year survival >95%. Widely invasive — 10-year survival 60-80%. Hürthle cell carcinoma — more aggressive, 10-year survival 50-70%.

Pregnancy + Bethesda IV: if diagnosed pre-pregnancy, surgical decision individualised (2nd trimester surgery safe, 1st trimester anomaly risk + 3rd trimester preterm risk). If detected during pregnancy: stable — postpartum surgery (3 months later), growing or high-risk US — 2nd trimester surgery. Investigation (FNA + molecular tests) safe in pregnancy.

Patient perspective — psychological impact: thyroid nodule diagnosis + "cancer possibility" creates high anxiety. Information + shared decision process improves trust. Support groups (Turkish Thyroid Foundation, online patient communities) helpful.

Lifestyle: iodine balance (Turkey adequate after salt iodination; avoid excess), selenium (some benefit in sub-clinical nodules), smoking cessation (lower thyroid cancer risk), regular health check (annual TSH).

Turkish Bethesda IV practice: major endocrine surgery centres (Istanbul: Memorial, Acıbadem, Anadolu, university hospitals; Ankara: Bayındır, Hacettepe; Izmir: Ege, KEAH) experienced. Molecular test in some private labs, still costly (limited adoption). Multidisciplinary endocrine tumour board decision is good standard.

Innovations: AI-assisted ultrasound analysis (TI-RADS scoring automated), molecular test advances (more sensitive, cheaper, local production), active surveillance strategy (especially <1 cm Bethesda IV — some clinicians initiated large series, evidence evolving), thermal ablation (radiofrequency, microwave — for benign nodules in some Turkish centres; for Bethesda IV in research). Related reading: our Istanbul thyroid surgery page.